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Background: Levetiracetam is a broad-spectrum antiseizure agent and one of 
the most commonly prescribed drugs for epilepsy. The aim of this work was to 
assess the effect of levetiracetam at its therapeutic range on the liver and kidney 
of pregnant albino rats.
Materials and methods: Forty pregnant rats were divided equally into two groups 
(I–II), Rats in the group I were gavaged 1.5 mL/day distilled water in two divided 
doses throughout pregnancy. Rats in the group II were gavaged 1.5 mL/day dis-
tilled water (containing 36 mg levetiracetam) in two divided doses throughout 
pregnancy. At the end of the experiment, blood samples were taken and the sera 
were separated and used for biochemical analysis. The kidneys and livers of both 
groups were excised and used for light and electron microscopic examination.
Results: Treatment with levetiracetam induced undesirable histopathological 
changes in the liver and kidney of pregnant albino rats. These changes were in 
the form of distortion of the hepatic architecture, dilatation of the central and 
the portal veins, widening of the Bowman’s spaces, thickening and disruption 
of the glomerular basement membrane, fusion and effacement of secondary 
foot processes, cytoplasmic vacuolation, and swollen mitochondria with loss of 
their cristae. Such changes were confirmed by alteration of certain biochemical 
parameters related to the liver and kidney functions.
Conclusions: Levetiracetam induced deleterious effects on the liver and kidney 
of pregnant albino rats. Further investigations are recommended to clarify the 
mechanism of levetiracetam toxicity. (Folia Morphol 2019; 78, 4: 809–817)
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INTRODUCTION
Epilepsy is a common sustained disorder affect-
ing approximately more than one million women of 
childbearing age [9]. The prevalence of epilepsy has 
been estimated to be 0.3–0.5% in pregnant women 
[33]. Pregnant women with epilepsy are advised to 
maintain antiepileptic drugs (AED) to diminish mater-
nal and foetal disturbance joined with seizures [22]. 
Pharmacological treatment options of epilepsy 
comprise conventional AED (valproate, phenobar-
bital and carbamazepine), in addition to the newer 
second generation agents (levetiracetam, gabap-
entin and topiramate) [15]. Conventional AED had 
good therapeutic effects and low treatment cost. 
However, some undesired effects associated with 
these drugs, such as memory deterioration and Ste-
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vens–Johnson syndrome [37]. The effectiveness of 
the second-generation drugs seems to be similar to 
that of the conventional AED. However, the newer 
drugs, such as levetiracetam, seem to offer a lower 
risk of interactions with other medications, simpler 
titration, and administration regimens, and improved 
tolerability [15].
Levetiracetam was developed as an analogue of 
piracetam, a drug used to improve cognitive function 
[24]. Levetiracetam is recognised for adjunct therapy 
of focal onset, primary generalised tonic–clonic, and 
myoclonic seizures in children and adults [25]. The 
correlation between binding affinity of levetiracetam 
analogues and their potency toward audiogenic sei-
zures suggests that a synaptic vesicle protein, SV2A, 
mediates the antiseizure effects of levetiracetam [26]. 
Oral absorption of levetiracetam is rapid and nearly 
complete, with peak plasma concentrations in 1.3 h. 
Two-thirds of the drug is excreted unchanged in the 
urine and the remainder as 2-pyrrolidone-N-butyric 
acid (inactive deaminated metabolite). There is no 
metabolism of levetiracetam in the liver as its me-
tabolism takes place in the blood [27]. 
Some authors reported a significant increase in 
gamma glutamyl transferase in an epileptic patient on 
levetiracetam monotherapy [5]. Study reported some 
adverse effects associated with levetiracetam therapy 
such as sleepiness, headaches, vomiting, inflamma-
tion of the nose and throat, and irritability [28].
Data on the safety of levetiracetam during preg-
nancy is still limited [3]. So, this work aimed to assess 
the effect of levetiracetam on the liver and kidney of 
pregnant albino rats. 
MATERIALS AND METHODS
Drug
Levetiracetam (Tiratam) was purchased from 
Al-Andalous for Pharmaceuticals-Egypt Industries. 
It was available in the form of tablets 500 mg each.
Adult dosing can begin with 1000 mg twice daily, 
increased to a maximum dosage of 3000 mg twice 
daily [23]. The chosen dose was 2000 mg/day. The 
equivalent dose for adult rat weighting about 200 g 
is 36 mg/day according to reference no. [20].
Animals
Sixty adult albino rats (20 males and 40 females) 
of local strain weighing about 200 g were obtained 
for this study. Care of animals and practices were 
provided with the Animal House, Faculty of Medicine 
(Girls), Al-Azhar University, Cairo, according to the 
Guide of the Care and Use of Laboratory Animals 
[11]. Each male rat was located with 2 virgin female 
rats in a cage for 24 h. In the morning, the first day 
of pregnancy was determined by the presence of the 
vaginal plug [16]. Each pregnant female was placed 
in an individual cage until the end of study.
Experimental design
The 40 pregnant rats were divided equally into 
two groups:
 — Group I (control) — each pregnant rat was gav-
aged 1.5 mL/day distilled water in two divided 
doses throughout pregnancy;
 — Group II (treated) — each pregnant rat was gav-
aged 1.5 mL/day distilled water (containing 36 mg 
levetiracetam) in two divided doses throughout 
pregnancy.
At the end of the experiment, blood samples were 
taken on the first day after delivery from the retro-or-
bital vein of all rats after ether inhalation [36]. The 
sera were separated by centrifugation of blood at 
3000 rpm for 15 min, then preserved at −20°C until 
used for biochemical analysis. Rats were sacrificed by 
cervical dislocation to avoid any chemical injury [6], 
their abdominal cavities were exposed by a midline 
incision, and the kidneys and livers were excised and 
used for light and electron microscopic examination.
Histopathological preparation
Preparation for light microscopic examination
Pieces of liver and kidney tissues from the control 
and treated groups were washed and fixed for 3 days 
in Bouin’s solution. Later, the tissues were dehydrated 
in ascending graded series of ethyl alcohol and pro-
cessed for paraffin wax embedding. Liver and kidney 
tissues blocks were cut using microtome into serial 
sections at a thickness of 7 μm. The sections were 
placed on glass slides and stained with haematoxylin 
and eosin (H&E), Masson’s trichrome for detecting 
collagen fibres and periodic acid Schiff (PAS reaction) 
for verifying the contents of carbohydrates [2]. For 
histopathological examination of liver and kidney tis-
sue a microscope (LEICA DM 750) and digital camera 
were used.
Preparation for electron microscopic examination
Small slices of the liver and kidney tissues were 
fixed quickly in 2.5% phosphate-buffered glutaralde-
hyde (pH 7.4). The specimens were then post-fixed 
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with 1% osmium tetroxide in the same buffer at 
41°C, dehydrated in graded ethanol and embed-
ded in epoxy resin [2]. Using LKB ultra-microtome, 
semithin sections (0.5 μm thick) were cut and 
stained with toluidine blue for light microscopic 
examination. Ultrathin sections were cut (80 nm), 
stained with uranyl acetate and lead citrate [10] 
and examined and photographed using electron 
microscope (JEOL1010 EX II, Japan) at the Regional 
Mycology and Biotechnology Centre, Al-Azhar Uni-
versity, Cairo, Egypt.
Biochemical indices
The level of some parameters of liver and kidney 
functions were measured using (BioSystems-BTS 310; 
Barcelona, Spain) which was calibrated for probes 
from rats. 
Liver function indices
Alanine aminotransferase (ALT) and aspartate ami-
notransferase (AST) enzymes levels were measured in 
IU/L using the methods of reference no. [32]. 
Kidney function indices 
Creatinine level in mg/dL was determined using 
the method of reference no. [8]. Blood urea nitrogen 
measurement in mg/dL was assessed according to 
reference no. [18]. 
Statistical analysis
Statistical analysis of the levels of ALT, AST, urea 
and creatinine in the studied groups were carried 
out using the SPSS statistical package, the data were 
analysed and statistical significance was determined 




Light microscopy. Examination of H&E stained 
liver transverse sections of group I (control group) 
revealed that the liver was built up of cords of hepat-
ocytes emitting from the central vein and spaced 
with blood sinusoids (Fig. 1A, B). The portal tract 
was built up of branches of portal vein, bile duct and 
Figure 1. Liver (A, B, D, E) and renal cortex (C, F) transverse sections (H&E ×400 magnification); A. Group I shows hepatocytes (H), central 
vein (CV), blood sinusoids (S) flat endothelial cells (E) and von Kupffer cells (K); B. Group I shows a branch of portal vein (PV), bile duct (BD) 
and lymph vessel (L); H — hepatocytes; N — vesicular basophilic nuclei; C. Group I shows the glomerulus (G), Bowman’s space (S), the 
Partial (pl) and visceral (vl) layers of Bowman’s capsule, proximal convoluted tubules (P), distal convoluted tubules (D) and collecting tubules 
(CT); D. Group II shows dilated central vein (CV), vacuolated cytoplasm (V) of hepatocytes, irregular deeply stained nuclei (N*), congested 
blood sinusoids (S); E. Group II shows dilated portal vein (PV), vacuolated cytoplasm (V) of hepatocytes, irregular deeply stained nuclei (N*), 
hepatic artery (HA) and bile duct (BD); F. Group II shows shrunken glomeruli (G), wide Bowman’s space (BS), deeply stained glomerular cell 
nuclei (arrow), the lining epithelium of the PCT (P), DCT (D) and collecting tubules (CT), have vacuolated cytoplasm (V) and small deeply 
stained nuclei (arrow). The lumina of some renal tubules contain cellular exfoliation (ex).
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lymph vessel (Fig. 1B). Masson’s trichrome staining 
showed minimal collagen fibres around the central 
vein (Fig. 2A) and the portal tract (Fig. 2B). PAS reac-
tion revealed deposition of PAS positive material in 
the hepatocytes (Fig. 3A).
Inspection of H&E stained liver transverse sections 
of group II (treated group) revealed that the hepatic 
cords did not have the normal radial arrangement, 
and the central vein was dilated (Fig. 1D). Most 
hepatocytes had cytoplasmic vacuoles, and some of 
their nuclei were small, irregular and deeply stained 
(Fig. 1D, E). The portal area showed a markedly dilat-
ed portal vein (Fig. 1E). Masson’s trichrome staining 
showed a markedly higher level of collagen-fibre 
distribution around the central vein (Fig. 2D) and 
the elements of the portal tract as compared with 
sections from control group (Fig. 2E). PAS reaction 
showed apparent reduction of the distribution of PAS 
positive material in the hepatocytes (Fig. 3C).
Electron microscopy. Examination of ultrathin 
sections of the liver of the group I (control group) 
revealed that the hepatocytes had intact plasma 
membranes and nuclei with demarcated nuclear en-
velopes. The nuclei contained prominent nucleoli 
and both euchromatin and heterochromatin. Their 
cytoplasm contained rounded or oval mitochondria, 
free ribosome, rough endoplasmic reticulum and 
glycogen granules (Fig.4A).
Examination of ultrathin sections of the liver of the 
Group II (treated group) showed histopathological 
changes in the hepatocytes. Some nuclei had irregular 
nuclear envelopes and absent nucleoli. The cytoplasm 
contained vacuolated areas, few glycogen granules, 
swollen mitochondria with loss of the cristae and matrix, 
rough endoplasmic reticulum and ribosomes (Fig. 4B).
Kidney
Light microscopy. Examination of H&E stained 
kidney sections of Group I (control group) showed 
the renal cortex was built up of Malpighian corpuscles 
and tubules (proximal convoluted tubules [PCT], distal 
convoluted tubules [DCT] and collecting tubules). The 
Malpighian corpuscles were formed of glomerulus 
surrounded by Bowman’s capsule (Fig.1C). The PCT 
and DCT were lined by cuboidal cells. The PCT had 
narrow lumina with brush border on their luminal 
surfaces; however, the DCT exhibited more number 
of lining cells, and wide lumina with no brush border. 
The collecting tubules were lined by 10–20 cuboidal 
epithelial cells (Fig.1C).
Figure 2. Liver (A, B, D, E) and renal cortex (C, F) transverse sections (Masson trichrome ×400 magnification); A. Group I shows normal 
distribution of collagen fibres (CF) around the central vein (CV); B. Group I shows normal distribution of collagen fibres (CF) around the portal 
tract (PT) and between the hepatocytes; C. Group I shows the collagen fibres (cf) in the parietal layer (pl) of the Bowman’s capsule, glomer-
ular capillaries (G) and in the basement membranes (BM) of renal tubules (T); D. Group II shows a higher level of collagen fibres (CF) distri-
bution is seen around the central vein (CV); E. Group II shows a higher level of collagen fibre (CF) distribution is seen around the elements of 
the portal tract (PT); F. Group II shows increase in the collagen fibres (cf) in the parietal layer (pl) of the Bowman’s capsule surrounding the 
glomerulus (G), in the basement membranes (BM) of renal tubules (T) and around the blood vessel (BV). 
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Figure 3. Liver (A, C) and renal cortex (B, D) transverse sections (PAS ×400 magnification); A. Group I shows the normal distribution of PAS 
positive material in the hepatocytes; B. Group I shows the PAS positive reaction in the parietal layer (pl) of Bowman’s capsule around the 
glomerulus (G), in the basement membranes (BM) of renal tubules and in the brush border (B) of the PCT (P); C. Group II shows reduction in 
the distribution of PAS positive material in the hepatocytes; D. Group II shows decrease in the PAS positive reaction in the parietal layer (pl) 
of Bowman’s capsule around the glomerulus (G), in the basement membranes (BM) of renal tubules and in the brush border (B) of the PCT (P).
Figure 4. Transmission electron microscopy of liver sections (TEM ×10,000 magnification); A. Groups I shows the cytoplasm of hepatocyte 
contains mitochondria (M), ribosomes (r), and glycogen granules (g). Notice the nucleus (N), nuclear envelope (ne), nuclear pores (arrow), 
heterochromatin (h), euchromatin (e) and prominent nucleolus (nu); B. Groups II shows the nuclei of hepatocytes (N) have irregular nuclear 
envelopes (ne*) and absent nucleoli. The cytoplasm contains vacuolated areas (V), mitochondria with a loss of cristae (M), ribosomes.
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Masson’s trichrome stained sections revealed nor-
mal distribution of collagen fibres in some elements 
of renal cortex (Fig. 2C). PAS-stained sections revealed 
a PAS-positive reaction in some elements of renal 
cortex (Fig. 3B). 
Examination of H&E stained kidney transverse 
sections of Group II showed renal corpuscles con-
taining some shrunken glomeruli with wide capsular 
spaces. Some of the glomerular tuft nuclei were small, 
irregular and deeply stained. Some of the epithelial 
cells lining the renal tubules (PCT, DCT and collecting 
tubules) showed cytoplasmic vacuolisation, intralumi-
nal exfoliation as well as small darkly stained irregular 
nuclei. The brush border of the some PCT became 
disrupted (Fig. 1F). Masson’s trichrome stained sec-
tions showed an apparent increase in the collagen 
fibres deposition in the parietal layer of Bowman’s 
capsule, around the blood vessels, and in the basal 
lamina of some renal tubules (Fig. 2F). PAS-stained 
sections revealed a weak reaction in the parietal layer 
of Bowman’s capsule, in the basal lamina of the renal 
tubules and in the brush border of the PCT (Fig. 3D).
Electron microscopy. Examination of ultrathin 
sections of the renal cortex of the Group I (con-
trol group) showed that the renal corpuscles was 
formed of glomerular capillaries lined by fenestrat-
ed endothelium and wrapped by podocytes. The 
podocytes had large irregular euchromatic nuclei, 
primary processes and secondary processes. Filtration 
slits were located between the secondary processes. 
The glomerular basement membrane appeared as 
a trilaminar structure (Fig. 5A). The epithelial cells 
lining the PCT were rested on a regular basal lamina 
that displayed basal infoldings ran perpendicular to 
it. Numerous rod-like mitochondria were lodged be-
tween the basal infoldings and a noticeable number 
of mitochondria of different sizes and shapes were 
situated on the upper portion of the cells (Fig. 5B). 
In addition to mitochondria, the cytoplasm harbours 
endoplasmic reticulum, ribosomes, Golgi complex 
Figure 5. Transmission electron microscopy of the ultrathin renal cortex section (TEM ×10,000 magnification); A. Group I shows a part of 
renal corpuscle. The glomerular capillary (C), fenestrated endothelium (F), the trilaminar glomerular basement membrane (BM), podocytes 
(PO) with their nuclei (N), primary cytoplasmic process (PP) and secondary processes (SP); B. Group I shows a part of cell lining the PCT,  
it has euchromatic nucleus (N), well demarcated nuclear envelope (ne), containing nuclear pores (NP), numerous apical microvilli (MV), basal 
infoldings (arrow), elongated mitochondria (M), ribosomes (r) and rough endoplasmic reticulum (R); C. Group I showing a part of cell lining the 
DCT, it has oval nucleus (N), well demarcated nuclear envelope (ne), nucleolus (Nu), basal infoldings (arrow), basement membrane (BM) and 
longitudinal arranged mitochondria (M); D. Group II shows a part of renal corpuscle, the podocyte (Po), primary processes (PP), distorted and 
flat secondary foot processes (SP). The basement membrane (BM) lining the glomerular capillaries (C) is thickened and its trilaminar structure 
is lost; E. Group II showing a part of cell lining the PCT, it has small nucleus (N) with increased heterochromatin ,ill demarcated irregular  
nuclear envelope (ne), less abundant apical microvilli (MV) and elongated mitochondria (M) with loss of their cristae; F. Group II showing  
a part of cell lining the DCT, it has small nucleus (N) with increased heterochromatin content and irregular ill-demarcated nuclear envelope (ne), 
loss of basal infoldings, disorganised mitochondria (M) with loss of their cristae, and rarefied cytoplasm (R).
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and lysosomes. The apex of the epithelial cells had 
tall, closely packed projections called microvilli. The 
nuclei of these epithelial cells were large, euchromatic 
with well demarcated nuclear membrane. The nuclei 
contained clumps of heterochromatin and nucleoli 
(Fig. 5B). The epithelial cells lining the DCT were rest-
ing on a regular basement membrane that exhibited 
basal infoldings ran perpendicular to it. Numerous 
elongated mitochondria were lodged between the 
basal infoldings (Fig. 5C).
Examination of ultrathin sections of the renal 
cortex of Group II showed histopathological changes. 
The renal corpuscle revealed thickening of the glomer-
ular basement membrane and loss of its trilaminar 
structure, some of the secondary foot processes were 
effaced or fused (Fig. 5D). The epithelial cells lining 
some PCT had small nuclei with increased heterochro-
matin contents and irregular ill demarcated nuclear 
envelope. Their mitochondria were longitudinally ar-
ranged with loss of cristae or swollen. Their cytoplasm 
exhibited primary lysosomes, and their microvilli were 
less abundant (Fig. 5E).The epithelial cells lining some 
DCT showed small nuclei with increased heterochro-
matin. Their cytoplasm exhibited rarefaction, loss of 
basal infoldings, disorganised mitochondria with loss 
of their cristae (Fig. 5F).
Biochemical results
Liver indices
Statistical analysis of the mean levels of ALT and 
AST in Groups I and II revealed significant (p < 0.05) 
increase in Group II as compared with Group I (Table 1).
Kidney indices
Statistical analysis of the mean levels of urea and 
creatinine in Groups I and II revealed significant 
(p < 0.05) increase in Group II as compared with 
Group I (Table 1).
DISCUSSION
The results of the current study revealed that treat-
ment of pregnant albino rats with levetiracetam in-
duced degenerative changes in their livers, specifically 
in the form of distortion of the hepatic architecture. 
Levetiracetam treatment also led to dilatation of the 
central and the portal veins, cytoplasmic vacuolation 
and swollen mitochondria with loss of their cristae, 
such histopathological changes were confirmed by 
elevation of liver enzymes.
These results are in line with reference no. [31] 
who reported an episode of acute liver injury imme-
diately following the treatment with levetiracetam in 
a patient with traumatic brain injury and restoration 
of normal liver function following stoppage of le-
vetiracetam. Some studies [1, 35] reported elevated 
serum alkaline phosphatase (ALP) level after leveti-
racetam treatment in children with epilepsy. Some 
authors observed that the serum ALP level returned 
to normal after the cessation of levetiracetam admin-
istration and concluded that the liver was the main 
cause of enzyme elevation after exclusion of other 
causes [35]. Some authors reported an elevation of 
the liver enzymes in a patient following levetiracetam 
administration for seizure prophylaxis. The enzymes 
returned to the normal level after levetiracetam dis-
continuation [27].
The current study showed that treatment of preg-
nant albino rats with levetiracetam induced nuclear 
changes in their liver cells. Such results were con-
firmed by a study [7] whose authors evaluated the 
genotoxic effect of levetiracetam (at doses 300 and 
600 mg/kg bw) in the liver and brain tissues of treated 
pregnant rats and their foetuses during pregnancy. 
They reported a significant increase in DNA damage 
as detected by alkaline Comet assay, and an appear-
ance of both apoptotic laddered and smeared DNA 
in the tissues tested.
Table 1. Means and standard deviations (SD) of alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea and creatinine  
of pregnant rats in Groups’ I–II
Measurements Pregnant rats at 1 day after delivery T test
Group I (n = 20) 
Mean ± SD, range
Group II (n = 20) 
Mean ± SD, range
t P
ALT [IU/L] 17.2 ± 2.69; 13–22 35.9 ± 4.817791, 31–43 2.144787 0.000
AST [IU/L] 12.6 ± 1.349897, 11–14 26.9 ± 2.960856, 24–31 2.160369 0.000
Urea [mg/dL] 37.39 ± 1.066094, 36–39 49.55 ± 1.480428, 47–51 2.119905 0.000
Creatinine [mg/dL] 0.663 ± 0.021108, 0.64–0.69 0.791 ± 0.008756, 0.78–0.8 2.178813 0.000
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On the other hand, the results of the present study 
were contrary to study whose authors evaluated the 
levetiracetam tolerability in 14 patients with liver 
disease and epilepsy. After 6 months of supervision, 
they reported that none of the patients showed de-
cline of liver function on the base of blood analysis 
[4]. Based on these observations, they assumed that 
levetiracetam was an agreeable treatment option in 
epileptic cases with liver impairment. The results of 
the present study were also contrary to some authors 
[17] who reported that chronic administration of le-
vetiracetam to rats at a therapeutic dose (54 mg/day) 
revealed no histopathological differences in their liver 
as compared to those of control. Some authors [34] 
mentioned that levetiracetam did not interact with 
the cytochrome P450 system and was the best drug 
of choice for cases with liver impairment.   
In the current study, Masson’s trichrome staining 
showed higher level of collagen-fibre distribution 
around the central vein and the elements of the por-
tal tract in levetiracetam treated group as compared 
with sections from the control group. Some authors 
mentioned that excessive collagen deposition in the 
liver was mediated by death of hepatocytes and acti-
vation of hepatic stellate cells. They added that lipid 
peroxidation including the generation of reactive 
oxygen species, could be implicated as a cause of 
excessive collagen deposition [29]. 
The current study revealed that treatment of preg-
nant albino rats with levetiracetam induced degener-
ative changes in their renal cortex. The changes were 
in the form of widening of the Bowman’s spaces, 
pyknosis of some of the glomerular tuft nuclei, thick-
ening and disruption of the glomerular basement 
membrane, and fusion and effacement of secondary 
foot processes. Levetiracetam treatment also led to 
cytoplasmic vacuolisation, intraluminal exfoliation, 
and disorganised mitochondria in the cells lining 
the renal tubules. In addition, levetiracetam treat-
ment led to an increased heterochromatin contents 
of some nuclei of the cells lining the renal tubules, 
such pathological changes were confirmed by signif-
icant elevation of the levels of urea and creatinine. 
These findings were in line with a study [14] whose 
authors presented occurrence of acute kidney injury in 
Drug Reaction with Eosinophilia and Systemic Symp-
toms (DRESS) 2 months after starting levetiracetam 
to a 75-year-old man with glioblastoma. Also, the 
results of the present study were in line with some 
researchers [30] who reported occurrence of an acute 
kidney injury 1 day after the initiation of levetiracetam 
treatment for new-onset seizures in a healthy 23-year-
-old female patient. Based on the time course of the 
patient’s elevation in the level of serum creatinine and 
the exclusion of other causes, the authors suggested 
that levetiracetam treatment was contributed to the 
acute kidney injury.
On the other hand, the results of the current study 
were contrary to some researchers [13] who evalu-
ated the clinical use of intravenous levetiracetam in 
patients with renal impairment and didn’t detect any 
major side effects any patients. So, they concluded 
that intravenous levetiracetam treatment was effec-
tive and safe in patients with renal impairment. The 
results of the present study also were contrary to 
a study [19] whose authors presented two paediatric 
cases of levetiracetam overdose for 1 month (115 
and 300 mg/kg/day) and didn’t observe remarkable 
severe side effects in their patients. So, they suggest-
ed that accidental treatment with an overdose of 
levetiracetam in children for long period was rarely 
accompanied with serious side effects.
In the current work, Masson’s trichrome staining 
showed higher level of collagen-fibre distribution in 
the parietal layer of Bowman’s capsule, and in the wall 
of some renal tubules in levetiracetam treated group 
as compared with sections from the control group. 
Such results may be caused by disturbance in oxidant/ 
antioxidant system. Such suggestion was supported 
by some authors who investigated the association 
of reactive oxygen species/antioxidant systems with 
kidney fibrosis following ischaemic/reperfusion injury 
[12]. They concluded that reactive oxygen species/ 
/oxidative stress was contributed to the progression 
of kidney fibrosis [12]. 
In the current study, the degenerative changes 
that were observed in the liver and kidney might be 
due to disturbance in the oxidant/antioxidant ratio. 
Such suggestion was supported by researchers [7] 
who explained that genotoxic potential of leveti-
racetam by decreased free radical neutralisation and/
or an increased production of free radicals.
CONCLUSIONS
Levetiracetam induced deleterious effects on the 
liver and kidney of pregnant albino rats. Continuous 
assessment of the liver and kidney functions during 
levetiracetam therapy is advised. In addition, further 
investigations are recommended to clarify the mech-
anism of levetiracetam toxicity.
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